PRF Technologies Ltd（PRFX）の株式分析PRFXPRF Technologies Ltd

PRF Technologies Ltd is an Israel-based company engaged primarily in pharmaceutical sector. The Company is a producer of speciality pharmaceuticals as well as energy analytics powered by artificial intelligence (AI). The Firm develops reformulated and sustained‑release drug‑delivery platforms that combine proven generic medicines with proprietary extended‑release systems to improve patient outcomes. One of the Company's products is PRF‑110 - a ropivacaine‑based formulation designed to deliver localised, extended postoperative analgesia. The Company also advances OcuRingTD, a bio‑erodible drug‑release ring integrated with intraocular lenses for continuous delivery of medications in cataract surgery.In the energy analytics sector the Company operates DeepSolar platform that provides AI‑powered monitoring, forecasting, and optimisation tools for solar asset performance. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

PainReform Ltd (PRFX) is not a good buy right now due to its current price of $0.96, a significantly negative year-to-date change of -72.50%, and a concerning forward P/E ratio of 0, indicating a lack of expected earnings growth. The main risk is the company's projected net margin for Q4 2025, which is -29541.18%, suggesting severe profitability issues.